A Potential Major Change in the Fight Against Pancreatic Cancer
Industry Buzz
“The fact that the long-term survival really correlated with T-cell response suggests that the vaccine caused this. The idea that you can target KRAS is really exciting." — Stephanie Dougan, PhD, an associate professor of cancer immunology and virology at the Dana-Farber Cancer Institute
Pancreatic cancer has long been one of the most challenging malignancies to treat, with a 5-year survival rate of just 13%.[] What's more, this type of cancer recurs in up to 80% of patients in the 2 years after resection.[]
However, recent advancements in immunotherapy, particularly the development of vaccines, are offering new hope. An early trial published on August 11, 2025, in Nature Medicine, found that a one-size-fits-all vaccine may prevent hard-to-treat pancreatic cancers from coming back.[]
Related: New lung cancer vaccine shows promiseMore about the trial
A recent Phase 1 trial (AMPLIFY-201) tested an off-the-shelf cancer vaccine called ELI-002 2P. This lymph node–targeting, amphiphile-based vaccine trains the immune system to target mutated KRAS proteins, the culprits in 93% of pancreatic cancers (and 50% of colorectal cancers).[]
Twenty-five people who’d had surgery for pancreatic or colorectal cancer received up to six priming doses of the vaccine. Thirteen people also received booster shots.[]
After almost 20 months of follow-up, researchers found that, on average, people went about 16 months before their cancer came back and lived for nearly 29 months overall—both better than what’s historically been seen with these cancers. []
The biggest improvements were in the patients whose immune systems mounted strong, targeted attacks against the KRAS mutation driving their cancer.[]
A larger Phase 2 trial is already underway to test durability and efficacy.[]
“The fact that the long-term survival really correlated with T-cell response suggests that the vaccine caused this. The idea that you can target KRAS is really exciting," said Stephanie Dougan, PhD, an associate professor of cancer immunology and virology at the Dana-Farber Cancer Institute in Boston.[]
Related: Inside a lifesaving 'last resort' clinical trial—have we finally solved the problem of chemo-resistant colon cancer?What this means for oncologists
In plain terms: An off-the-shelf vaccine is showing real potential to prevent pancreatic cancer recurrence, with a manageable safety profile and impressive early immunogenicity.
Unlike personalized mRNA vaccines—which require time, cost, and bespoke manufacturing—ELI-002 2P offers scalability and may reach more patients quickly.
However, early-phase trials come with caveats: small sample sizes, no comparator arms, and short follow-up durations. The real test lies in upcoming trials to confirm whether strong immune responses translate directly into prolonged survival.
As for what's next for docs in this space:
Watch for Phase 2 results. These will tell us if extended survival truly hinges on the vaccine—and if it becomes a part of standard adjuvant therapy.
Stay alert to patient selection. Understanding which patients mount robust KRAS-specific responses will be key—especially in the context of co-administered therapies like chemotherapy or immunotherapy.
Consider immune monitoring. Tracking T-cell responses might become a new biomarker for predicting recurrence risk and guiding follow-up.
Advocate for trial participation. Patients with resected, KRAS-driven pancreatic cancer may benefit from early access in Phase 2 and beyond.
Collaborate on combinatorial strategies. Combining vaccines like ELI-002 2P with checkpoint inhibitors or novel immunotherapies could enhance effectiveness, especially in patients with minimal residual disease.